<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607906</url>
  </required_header>
  <id_info>
    <org_study_id>AXO110461</org_study_id>
    <nct_id>NCT00607906</nct_id>
  </id_info>
  <brief_title>First-Time-in-Humans Study to Assess Safety, Pharmacokinetics &amp; Pharmacodynamics of SB756050</brief_title>
  <official_title>A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered SB756050 in Healthy Volunteers and in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics,&#xD;
      and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2007</start_date>
  <completion_date type="Actual">March 10, 2008</completion_date>
  <primary_completion_date type="Actual">March 10, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events:</measure>
    <time_frame>each visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical laboratory:</measure>
    <time_frame>day -1, day 2 each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>electrocardiogram (ECG):</measure>
    <time_frame>day 1 each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs assessments:</measure>
    <time_frame>day -1, day 1 each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma drug concentrations:</measure>
    <time_frame>Day 1 each dosing level</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma blood sugar &amp; other parameter concentrations:</measure>
    <time_frame>Day 1 Period 4 following meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between drug concentrations &amp; blood sugar levels:</measure>
    <time_frame>day 1 period 4</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 5 milligrams, 15 milligrams, 50 milligrams, or 100 milligrams.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 100 milligrams, 200 milligrams, 300 milligrams, or 400 milligrams.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive oral immediate release capsules of SB-756050 with a dose of 150 milligrams. Subjects will also receive oral modified release capsules of SB-756050 with doses of 150 milligrams, 300 milligrams, or 400 milligrams.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive SB-756050 in this additional cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive oral modified release capsules of SB-756050 with doses of 50 milligrams, 150 milligrams or 400 milligrams. Subjects will also receive immediate release oral capsules of SB-756050 with a dose of 150 milligrams.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-756050 immediate release capsule</intervention_name>
    <description>SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.</description>
    <arm_group_label>Subjects receiving treatment in cohort A1</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort A2</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort A3</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort A4</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-756050 modified release capsule</intervention_name>
    <description>SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.</description>
    <arm_group_label>Subjects receiving treatment in cohort A3</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort B1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will also receive placebo capsules.</description>
    <arm_group_label>Subjects receiving treatment in cohort A1</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort A2</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort A3</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort A4</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort B1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Subjects&#xD;
&#xD;
          -  Healthy male or female subject as determined by a responsible physician, based on a&#xD;
             medical evaluation including history, physical examination, vitals signs, laboratory&#xD;
             tests, and cardiac monitoring.&#xD;
&#xD;
          -  Female subjects must be of non-childbearing potential including pre-menopausal women&#xD;
             with documented (medical report verification) hysterectomy, tubal ligation, or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of&#xD;
             spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/ml or 6 weeks postsurgical&#xD;
             bilateral oophorectomy with or without hysterectomy.&#xD;
&#xD;
          -  18 - 60 years of age, inclusive, at the time of signing and dating the informed&#xD;
             consent.&#xD;
&#xD;
          -  BMI (body mass index) within the range 20-30 kg/m2, inclusive.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Diabetic Subjects&#xD;
&#xD;
          -  Male or female subjects, 18 - 60 years of age, inclusive, at the time of signing the&#xD;
             informed consent&#xD;
&#xD;
          -  Female subjects must be of non-childbearing potential including pre-menopausal women&#xD;
             with documented (medical report verification) hysterectomy, tubal ligation, or double&#xD;
             oophorectomy or postmenopausal defined as 12 months of spontaneous amenorrhea or 6&#xD;
             months of spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/ml or 6 weeks&#xD;
             postsurgical bilateral oophorectomy with or without hysterectomy.&#xD;
&#xD;
          -  Subjects should have no significant known medical conditions other than T2DM.&#xD;
&#xD;
          -  BMI (body mass index) within the range 25-35 kg/m2, inclusive.&#xD;
&#xD;
          -  T2DM diagnosed at least 3 months prior to Screening with&#xD;
&#xD;
               -  Fasting plasma glucose (FPG) level ≤ 220mg/dL at the Screening visit,&#xD;
&#xD;
               -  FPG level ≤ 250 mg/dL on Day -1 of Period 1&#xD;
&#xD;
               -  For subjects taking no antidiabetic medications: HbA1c between 7 and 10%,&#xD;
                  inclusive, at Screening visit&#xD;
&#xD;
               -  For subjects taking metformin or a sulfonylurea: HbA1c between 6.5 and 9.5%,&#xD;
                  inclusive, at Screening visit&#xD;
&#xD;
          -  Subjects must be taking either no anti-diabetic medication, or metformin as&#xD;
             monotherapy, or a sulfonylurea as monotherapy. (Subjects taking BOTH metformin and a&#xD;
             sulfonylurea are not qualified for the trial). If taking metformin or a sulfonylurea,&#xD;
             the dose must have been stable for at least 3 months prior to screening, and the&#xD;
             subject must be willing to wash out from metformin or sulfonylureas from Day -7 prior&#xD;
             to Period 1, through discharge from Period 4.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As a result of the medical interview, physical examination, or screening&#xD;
             investigations, the Investigator considers the subject unfit for the study.&#xD;
&#xD;
          -  Has any of the following laboratory abnormalities:&#xD;
&#xD;
               -  Positive pre-study Hepatitis B surface antigen, positive Hepatitis C, or HIV&#xD;
                  result.&#xD;
&#xD;
               -  History of uncorrected thyroid dysfunction or an abnormal thyroid function test&#xD;
                  assessed by TSH at Screening&#xD;
&#xD;
               -  A positive pre-study drug/urine screen. A minimum list of drugs that will be&#xD;
                  screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids&#xD;
                  and benzodiazepines.&#xD;
&#xD;
               -  A pre-study urine cotinine screen indicating use of tobacco/ nicotine containing&#xD;
                  products.&#xD;
&#xD;
          -  Has a history of any gastrointestinal or hepatic conditions that could impact&#xD;
             absorption of the investigational compound.&#xD;
&#xD;
          -  Has QTc at Screening &gt; 450 msec. Note that if the initial QTc value is prolonged, the&#xD;
             ECG should be repeated two more times (with 5 minutes between ECG readings) and the&#xD;
             average of the 3 QTc values used to determine eligibility.&#xD;
&#xD;
          -  Has clinically significant rhythm abnormalities identified during 24-hour Screening&#xD;
             Holter assessment.&#xD;
&#xD;
          -  History of regular alcohol consumption averaging &gt;7 drinks/week for women or &gt;14&#xD;
             drinks/week for men. One drink is equivalent to 12 g alcohol (which equals 5 ounces&#xD;
             (150 mL) of wine, 12 ounces (360 mL of beer or 1.5 ounces (45 mL) of 80 proof&#xD;
             distilled spirits) within 6 months of screening.&#xD;
&#xD;
          -  Smoked or used tobacco or nicotine-containing products within the previous 6 months.&#xD;
&#xD;
          -  Has participated in a clinical trial and has received a drug or a new chemical entity&#xD;
             within 30 days or 5 half-lives, or twice the duration of the biological effect of any&#xD;
             drug (whichever is longer) prior to the first dose of current study medication.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication. Acetaminophen may be used as&#xD;
             needed for adverse events; however, use should be restricted to 4 hours after dosing&#xD;
             if possible with a preferred maximum dose of 2 grams in 24 hours.&#xD;
&#xD;
          -  Unwilling to abstain from&#xD;
&#xD;
               -  Caffeine-or xanthine-containing products for 24 hours prior to dosing until the&#xD;
                  final post-dose assessment at each treatment level.&#xD;
&#xD;
               -  Use of illicit drugs&#xD;
&#xD;
               -  Alcohol for 24 hours prior to dosing until final post-dose assessment at each&#xD;
                  treatment level.&#xD;
&#xD;
               -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7&#xD;
                  days prior to the first dose of study medication until collection of the final&#xD;
                  pharmacokinetic and pharmacodynamic blood samples.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the physician responsible,&#xD;
             contraindicates their participation. This includes sensitivity to heparin, if heparin&#xD;
             will be used to maintain catheter patency.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood in excess of 500 mL&#xD;
             within a 56 day period.&#xD;
&#xD;
          -  Subject is either an immediate family member of a participating investigator, study&#xD;
             coordinator, employee of an investigator; or is a member of the staff conducting the&#xD;
             study.&#xD;
&#xD;
        Healthy Subjects&#xD;
&#xD;
          -  As a result of the medical interview, physical examination, or screening&#xD;
             investigations, the Investigator considers the subject unfit for the study.&#xD;
&#xD;
          -  Has any of the following laboratory abnormalities:&#xD;
&#xD;
               -  Positive pre-study Hepatitis B surface antigen, positive Hepatitis C, or HIV&#xD;
                  result.&#xD;
&#xD;
               -  History of uncorrected thyroid dysfunction or an abnormal thyroid function test&#xD;
                  assessed by TSH at Screening. (NOTE: subjects with hypothyroidism on a stable&#xD;
                  dose of thyroid replacement therapy for at least 3 months prior to Screening and&#xD;
                  who have a screening thyroid stimulating hormone (TSH) within the normal range&#xD;
                  may participate.)&#xD;
&#xD;
               -  ALT and/or AST &gt; 2 times the upper limit of normal at screening or prior to the&#xD;
                  first dose.&#xD;
&#xD;
               -  Fasting triglycerides &gt; 450mg/dL at screening or prior to the first dose.&#xD;
&#xD;
               -  Total Bilirubin &gt; 1.5 times the upper limit of normal at screening or prior to&#xD;
                  the first dose&#xD;
&#xD;
               -  A positive pre-study drug/urine screen. A minimum list of drugs that will be&#xD;
                  screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids&#xD;
                  and benzodiazepines.&#xD;
&#xD;
               -  A pre-study urine cotinine screen indicating use of tobacco/ nicotine containing&#xD;
                  products.&#xD;
&#xD;
          -  Significant renal disease or loss of a kidney&#xD;
&#xD;
          -  Significant ECG abnormalities,&#xD;
&#xD;
          -  Systolic pressure &gt; 150 mmHg or &lt;80 mmHg or diastolic blood pressure &gt; 95 mmHg or &lt;60&#xD;
             mmHg at screening. Blood pressure assessments may be repeated once if needed, allowing&#xD;
             adequate time for subject to rest.&#xD;
&#xD;
          -  Previous use of insulin as a treatment within 3 months of Screening, or for &gt;2 weeks&#xD;
             when used for acute illness in the last 12 months prior to Screening, or if used for&#xD;
             more than 1 year when associated with GDM.&#xD;
&#xD;
          -  Has a history of any of the following conditions:&#xD;
&#xD;
               -  Clinically significant symptoms of gastroparesis&#xD;
&#xD;
               -  Cholelithiasis or obstructive or inflammatory gallbladder disease within 3 months&#xD;
                  prior to Screening&#xD;
&#xD;
               -  Gastrointestinal disease that could affect fat or bile acid absorption, including&#xD;
                  inflammatory bowel disease, chronic diarrhea, Crohn's or malabsorption syndromes&#xD;
                  within the past year&#xD;
&#xD;
               -  Gastrointestinal surgery&#xD;
&#xD;
               -  Chronic or acute pancreatitis&#xD;
&#xD;
          -  History of regular alcohol consumption averaging &gt;7 drinks/week for women or &gt;14&#xD;
             drinks/week for men. 1 drink is equivalent to (12 g alcohol) = 5 ounces (150 mL) of&#xD;
             wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of 80 proof distilled&#xD;
             spirits) within 6 months of screening.&#xD;
&#xD;
          -  Smoked or used tobacco or nicotine-containing products within the previous 6 months.&#xD;
&#xD;
          -  Has participated in a clinical trial and has received a drug or a new chemical entity&#xD;
             within 30 days or 5 half-lives, or twice the duration of the biological effect of any&#xD;
             drug (whichever is longer) prior to the first dose of current study medication.&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Is taking prohibited medications:&#xD;
&#xD;
               -  Acetaminophen may be used as needed for adverse events; however, use should be&#xD;
                  restricted to 4 hours after dosing if possible with a preferred maximum dose of 2&#xD;
                  grams in 24 hours.&#xD;
&#xD;
               -  The use of anti-diabetic agents other than metformin or sulfonylureas is reason&#xD;
                  for exclusion and subjects will not be allowed to wash off of unapproved&#xD;
                  anti-diabetic medications in order to qualify for participation in this study.&#xD;
                  Subjects taking BOTH metformin and a sulfonylurea are not qualified for the&#xD;
                  trial.&#xD;
&#xD;
               -  Subjects must wash out from the following medications during the 7-day period&#xD;
                  prior to first dose, and must remain off these medications through discharge from&#xD;
                  period 4: metformin, sulfonylureas, statins, fat absorption blocking agents, bile&#xD;
                  acid sequestrants&#xD;
&#xD;
               -  All other prescription or non-prescription drugs, including vitamins, herbal and&#xD;
                  dietary supplements (including St John's Wort) are prohibited within 7 days or 5&#xD;
                  half-lives (whichever is longer) prior to the first dose of study medication and&#xD;
                  through discharge from Period 4.&#xD;
&#xD;
          -  Unwilling to abstain from&#xD;
&#xD;
               -  Caffeine-or xanthine-containing products for 24 hours prior to dosing until the&#xD;
                  final post-dose assessment at each treatment level&#xD;
&#xD;
               -  Use of illicit drugs&#xD;
&#xD;
               -  Alcohol for 24 hours prior to dosing until final post-dose assessment at each&#xD;
                  treatment level&#xD;
&#xD;
               -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice from 7&#xD;
                  days prior to the first dose of study medication until collection of the final&#xD;
                  pharmacokinetic and pharmacokinetic blood samples&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the physician responsible,&#xD;
             contraindicates their participation. This includes sensitivity to heparin, if heparin&#xD;
             will be used to maintain catheter patency.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood in excess of 500 mL&#xD;
             within a 56 day period.&#xD;
&#xD;
          -  Subject is either an immediate family member of a participating investigator, study&#xD;
             coordinator, employee of an investigator; or is a member of the staff conducting the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>diabetes</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>AXO110461</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AXO110461</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AXO110461</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AXO110461</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AXO110461</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AXO110461</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AXO110461</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

